Eiken Chemical Co Ltd

Chart & Performance

D1W1MN

P/E

28.28

P/S

1.86

EPS

76.06

Div Yield, %

2.59%

Shrs. gr., 5y

-0.04%

Rev. gr., 5y

2.29%

Revenues

40.05b

-7.44%

Net income

2.63b

-54.08%

CFO

3.81b

-49.76%

Dividend

Mar 28, 20250 JPY/sh

Earnings

Jan 28, 2025

Profile

Eiken Chemical Co., Ltd. manufactures and sells clinical diagnostics and equipment in Japan. The company is involved in developing clinical diagnostic aids to various aspects of contemporary medicine, including biochemical, immunological, serological, dry chemical diagnosis, and automatic analyzers. It also develops and supplies OC-SENSOR, an automated immunochemical fecal test for detecting gastrointestinal bleeding associated with disorders, such as colorectal cancer, polyps, and diverticulitis. In addition, the company offers real-time turbidi meters, and homeothermal equipment; amplification kits and fluorescence detection reagents for research use; and detection kits. Further, it manufactures a range of products that are used in the field of microbiology; and provides other products comprising immunological and serological reagents. The company was formerly known as Nihon Eiyokagaku Co., Ltd. and changed its name to Eiken Chemical Co., Ltd. in 1969. Eiken Chemical Co., Ltd. was founded in 1939 and is headquartered in Tokyo, Japan.

URL

https://www.eiken.co.jp/

IPO date

Jan 29, 1990

Employees

754

Domiciled in

Incorporated in

Valuation

Order:

Title JPY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title JPY in thousands, except ratios and share amounts	2024‑03	2023‑03	2022‑03	2021‑03	2020‑03	2019‑03	2018‑03	2017‑03	2016‑03	2015‑03
Income
Revenues	40,052,000 -7.44%	43,271,000 0.62%	43,004,000 11.22%
Cost of revenue	27,267,000	26,830,000	25,839,000
Unusual Expense (Income)
NOPBT	12,785,000	16,441,000	17,165,000
NOPBT Margin	31.92%	38.00%	39.91%
Operating Taxes	869,000	1,856,000	2,263,000
Tax Rate	6.80%	11.29%	13.18%
NOPAT	11,916,000	14,585,000	14,902,000
Net income	2,634,000 -54.08%	5,736,000 -7.75%	6,218,000 23.28%
Dividends	(1,927,000)	(2,033,000)	(1,699,000)
Dividend yield	2.60%	3.49%	2.64%
Proceeds from repurchase of equity	(4,707,000)
BB yield	6.35%
Debt
Debt current	384,000	390,000	393,000
Long-term debt	5,286,000	5,228,000	4,989,000
Deferred revenue		(485,000)	(511,000)
Other long-term liabilities	379,000	379,000	381,000
Net debt	(18,139,000)	(21,287,000)	(19,326,000)
Cash flow
Cash from operating activities	3,806,000	7,575,000	7,769,000
CAPEX	(1,976,000)	(3,278,000)	(4,893,000)
Cash from investing activities	(2,216,000)	(316,000)	(5,044,000)
Cash from financing activities	(6,694,000)	(2,095,000)	1,200,000
FCF	10,384,000	12,589,000	11,975,000
Balance
Cash	16,308,000	18,654,000	16,444,000
Long term investments	7,501,000	8,251,000	8,264,000
Excess cash	21,806,400	24,741,450	22,557,800
Stockholders' equity	43,763,000	44,553,000	40,925,000
Invested Capital	28,877,600	28,168,550	25,998,200
ROIC	41.78%	53.85%	61.02%
ROCE	25.22%	30.79%	34.98%
EV
Common stock shares outstanding	37,051	37,281	37,237
Price	2,000.00 27.96%	1,563.00 -9.50%	1,727.00 -20.16%
Market cap	74,101,340 27.17%	58,270,203 -9.39%	64,308,299 -20.08%
EV	55,962,340	36,983,203	44,982,299
EBITDA	15,111,000	18,566,000	19,223,000
EV/EBITDA	3.70	1.99	2.34
Interest	17,000	16,000	7,000
Interest/NOPBT	0.13%	0.10%	0.04%